Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.

doi:10.1038/srep19552

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.

Scientific reports - 21 Jan 2016

Huang Kie Kyon, Jang Kang Won, Kim Sangwoo, Kim Han Sang, Kim Sung-Moo, Kwon Hyeong Ju, Kim Hye Ryun, Yun Hwan Jung, Ahn Myung Ju, Park Keon Uk, Ramnarayanan Kalpana, McPherson John R, Zhang Shenli, Rhee Je-Keun, Vettore André L, Das Kakoli, Ishimoto Takatsugu, Kim Joo Hang, Koh Yoon Woo, Kim Se Hun, Choi Eun Chang, Teh Bin Tean, Rozen Steven G, Kim Tae-Min, Tan Patrick, Cho Byoung Chul

Abstract excerpt

Dacomitinib, an irreversible pan-HER inhibitor, had shown modest clinical activity in squamous cell carcinoma of head and neck (SCCHN) patients. Therefore, validated predictive biomarkers are required to identify patients most likely to benefit from this therapeutic option. To characterize the genetic landscape of cisplatin-treated SCCHN genomes and identify potential predictive biomarkers for dacomitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Directed DNA Polymerase

Share to Gene Silencing

Share to Head and Neck Neoplasms

Share to Quinazolinones

Share to Recombinational DNA Repair

Share to RNA, Small Interfering

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 26790612
DOI: 10.1038/srep19552
PMCID: PMC4726344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.PMID 26790612Read ↗

The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy.Semantic proximity Read ↗

REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinomaSemantic proximity Read ↗

The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy.Semantic proximity Read ↗

Overexpression of NEIL3 associated with altered genome and poor survival in selected types of human cancer.Semantic proximity Read ↗

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.Semantic proximity Read ↗

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapySemantic proximity Read ↗

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.Semantic proximity Read ↗

REV1: A novel biomarker and potential therapeutic target for various cancersSemantic proximity Read ↗

Dynamic evolution of cervical cancer mutations during chemoradiation using novel sampling approachSemantic proximity Read ↗

REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer CellsSemantic proximity Read ↗

Senataxin modulates resistance to cisplatin through an R-loop mediated mechanism in HPV-associated Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.